Researchers at Leuven Cancer Institute used oncolytic viruses to test potency in lysing glioblastomas. The viruses studied showed high oncolytic potency across cell lines. 

Dirk Daelemans, et all. Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes. https://doi.org/10.1016/j.omton.2026.201263

In this study, researchers evaluated 15 clinically relevant oncolyctic viruses across a panel of 14 patient-derived GBM cell lines (PDCLs) and healthy primary neural models to identity the core molecular determinants driving viral efficacy and neurotoxicity. The research team utilized Primary Human Neurons, Immortalized Human Brain Microglia, Defined Media, and AlphaBioCoat™to model non-cancerous brain physiology, assess off-target cytotoxicity, and benchmark tumor selectivity.

Researchers at UK Dementia Research and Brain Sciences Institute, Imperial College London, London, UK used Neuromics' Human Brain Microvascular Endothelial Cells (HBMVECS or BECS) to study gene expression in Cerebral small vessel disease, and Alzheimer's disease.

In short, Cerebral small vessel disease (SVD) often coexists with Alzheimer’s disease (AD), and brain endothelial cells (BECs) express genes associated with AD risk. To examine how genetic risk intersects with neurovascular cell regulation, we mapped gene regulomes across human BECs, mural cells, and other brain cell types. We found that AD heritability is predominantly immune related, with modest enrichment in BECs.

Image: (A) Schematic of nuclei isolation and epigenomic profiling of brain cell types from resected and post-mortem cortical samples. (B) UCSC genome browser visualization of H3K27ac and H3K4me3 CUT&Tag at cell-type-specific marker gene loci.(C) EWCE analysis of cell-type-specific promoters for resected and post-mortem brain cell types and for primary pericytes and BECs in brain single-cell gene expression.5∗Benjamini-Hochberg-corrected q < 0.05; ∗∗Benjamini-Hochberg-corrected q = 0. (D) CAMERA analysis of cell-type annotations from brain single-cell gene expression5 using differential promoters from resected and post-mortem brain cell types.

Their important findings demonstrate a genetic rationale for drug prioritization. Importantly, the results present targets and potential avenues for therapeutic intervention in AD and SVD, which have the potential to lower dementia risk.

1. Kevin Chris Ziegler, Aydan Askarova, Alexi Nott et al (2025). The Brain Neurovascular Epigenome and Its Association with Dementia. Neuron. doi: 10.1016/j.neuron.2025.10.001

All Customer Publications

Yvonne Adams, Anja T.R. Jensen (University of Copenhagen) manufactured Organioids using Neuromics' Primary Human Astrocytes and Human Brain Microvascular Endothelial Cells to study Plasmodium falciparum erythrocyte membrane protein 1 variants induce cell swelling and disrupt the blood–brain barrier in cerebral malaria.

Cerebral malaria (CM) is caused by the binding of Plasmodium falciparum–infected erythrocytes (IEs) to the brain microvasculature, leading to inflammation, vessel occlusion, and cerebral swelling.

Image 1: 3D BBB spheroids are composed of three different cell types. (A) FACS histogram showing pericytes (NG2, neural/glial antigen 2), astrocytes (GFAP, glial fibrillary acidic protein), and human cerebral microvascular endothelial cells (hCMEC/D3 and CD31).

Image2: ICAM-1–enriched microvilli and transmigratory ring/docking structures on brain hCMEC/D3 endothelial cells. (A–C) hCMEC/D3 brain endothelial cells were incubated with parasites.

This is first time the presence of intact, mature P. falciparum IEs within brain microvascular endothelial cells both in vitro and in vivo.  The data on the enhanced binding and internalization of IEs suggest that the same approach will be necessary to counteract not only the effects of cytoadhesion but also the subsequent contribution to potentially lethal brain swelling in CM.

Explore more topics on 3-D "in-vivo" Like HuCell Models

Explore More Topics on Antibodies.

Read more posts about Fetal Bovine Serum from Neuromics.

We often highlight the countless areas of study that our antibodies can help researchers. We encourage you to check out all our primary antibodies here along with the many applications they've been used for here.

Now, the three most prominent and common uses for our antibodies are in cancer, neuroscience, and pain research. Well, what do you know? Already this month, new research has been released utilizing our antibodies in those three corresponding areas. We'd like to highlight those studies below.

Image: Staining of various glioblastoma cell lines with Neuromics Humanin antibody (cat. RA19000).

In the first study, Korean researchers used our Humanin rabbit polyclonal antibody (cat. RA19000) to study glioblastoma progression. In their release of preliminary research, the investigators found humanin to encourage glioblastoma progression via the integrin alpha V (ITGAV)–TGF beta (TGF) signaling axis. Read the full publication here.

A couple months ago, we published a blog post highlighting the 20+ years of results our pain antibodies have demonstrated (learn more here). It didn't take long into 2023 to add on another year to the total. Earlier this month, researchers from the University of Texas Health Science Center at San Antonio published preliminary findings with the help of Neuromics' Guinea Pig VR1 C-Terminus/TRPV1 antibody (cat. GP14100).

Image: Immunofluorescent images of WGA and TRPV1 (cat. GP14100) staining of TG tissues in male and female mice with colocalization of TRPV1 and WGA indicated with arrows.

The researchers noted that orofacial pain is clinically understood to be more common in females than males. However, despite this understanding, no research had been done to look at what factors cause this occurrence. Using mice as a model, the investigators began to characterized the sex-specific differences in gene expression, biological pathways, and molecular function of tongue sensory neurons. Our antibody played a big part in their analysis. We encourage you to check out the full publication below to learn more about their findings.

When discussing our primary antibodies for pain and neuroscience research, we always point to the 20+ years of results. Why wouldn't we? That's quite an accomplishment. Several of these antibodies have been consistently used in published research for over two decades. Over the weekend, two more studies were released using our antibodies in these familiar applications.

Image: Increased expression of mu opioid receptor levels in the ipsilateral lumbar DRGs of CPSS rats.

Researchers from Johns Hopkins University released pain research with the help of our rabbit Mu Opioid Receptor antibody (cat. RA10104). The paper introduced a rat model to study chronic pain after spine surgery (CPSS). By performing surgery on the rats and looking for symptoms of CPSS after the procedure, it provides a model to study the mechanisms of the disorder. You can read the full paper here.

At the core of the Neuromics portfolio are reagents with applications in neuroscience research. As a result, we see a large portion of references relating to neurodegenerative diseases, the brain, pain, and other neuroscience fields.

And while our collection of customer publications proves that our products can be used for so much more (see for yourself here), that theme of neuroscience research continued this past week. Two publications were released using our research tools in Parkinson's disease (PD) studies that we'd like to highlight.

Image: GFAP staining (cat. RA22101) of various parts of the PD mouse brain.

In the first study, researchers from Korea used our Rabbit GFAP Polyclonal Antibody (cat. RA22101). They evaluated various antihistamines as potential therapies for patients with PD. After analyzing South Korean patient data and using various animal models, they found that fexofenadine is a potentially effective option to treat PD. Our antibody was used to stain various parts of the mouse brain in a PD model. We encourage you to check out the full publication here.

Over the past few weeks, we've seen a bunch of new publications come through from customers highlighting the capabilities of our many products. These include two studies using some of our highly touted pain research antibodies in migraine and neuropathic pain research. Additionally, one of our primary human cell types was utilized in pancreatic cancer research. You can explore all citations using Neuromics products here.

In the first piece of research, migraine researchers used two of our Neuropeptide Y (NPY) receptor antibodies. The investigators injected mice with glyceryl trinitrate (GTN) in the medial habenula (MHb) to produce a migraine mouse model. Upon microinjections of NPY, the signs of migraine decreased in the GTN mice. Using our Rabbit Polyclonal NPY Y1 Receptor Antibody (cat. RA24506) and Rabbit Polyclonal NPY Y2 Receptor Antibody (cat. RA14112), the scientist observed activation of NPY Y1 receptors, but not NPY Y2 receptors.

Image: Immunofluorescent staining showing the expression of the Y1 receptor (cat. RA24506) and Y2 receptor (cat. RA14112) in the MHb of GTN mice after microinjections of NPY.

Scientists from Augusta University used our Premium Imported Fetal Bovine Serum (FBS) (cat. FBS002) to culture RAW264.7 cells, a mouse macrophage line, in preliminary research released this month. They were looking at ways to deliver nutraceuticals in oral capsules or beverages that allow the body to better process the nutrients.

Image: RAW264.7 cells culture using Neuromics Fetal Bovine Serum (FBS).

The study presents the Facilitated Self-Assembling Technology (FAST) platform, a clean-label method for generating bioavailable nutraceutical nanoparticles. Many other platforms use harmful compounds or are not able to keep nutraceutical compounds stable.

Over the past few years, researchers from Dartmouth have utilized our GFP-expressing U87 MG cells (cat. TR01-GFP) in surgical imaging research. They have been using the cells to evaluate various contrast agents for fluorescent-guided surgery by implanting our cells in mouse models. Last week, they published another study with fascinating results.

In their initial paper, released last year, the researchers identified TMR-PEG1k as the preferred contrast agent when compared with others. Then, earlier this year, the same group released a study highlighting the need for standardized methods to study contrast agents.

Image: Neuromics GFP Expressing U87 MG Cells were incubated with two potential contrast agents in surgical research.

In this week’s research, the investigators developed a near-infrared version of TMR-PEG1k to address some of the agent's shortcomings. Being in the visible regime, TMR-PEG1k is excellent for superficial tissue, but doesn’t allow for subsurface penetration, unlike a near-infrared agent. Therefore, the researchers developed a cyanine 7 version of the agent as an alternative.

As part of our commitment to supporting innovative research, Neuromics continually seeks to introduce new human cell types that meet the needs of researchers. Earlier this month, we introduced several new cell types for studying diabetes and obesity. Now, we've turned our attention back to our selection of human iPSC-related cells, with the addition of three cell types. As a reminder, we offer a wide range of iPSC-derived neural cell types (check them out).

iPSC-derived models are transforming neuroscience research - especially for diseases like ALS, Parkinson’s, and Alzheimer’s. Models from diseased donors open the door for new assays and drug discovery approaches.

Image: Neuromics Human iPSC - Sensory Neurons (cat. IPS006) in culture.

Here are the new cell types:

• Human iPSC (cat. IPS013): a versatile cell line for custom differentiation or disease modeling.
• Human iPSC - Motor Neurons (ALS Patient, Sporadic) (cat. IPS014): derived from a patient with sporadic ALS, providing a physiologically relevant model for studying disease mechanisms
• Human iPSC - Motor Neurons (TDP-43 M337V, Homozygous) (cat. IPS015): a genetic model capturing a well-characterized ALS-linked mutation in TARDBP.

Neuromics is pleased to announce the release of five new human cell types for research in diabetes and obesity. This introduction builds on an existing inventory of human cells, specifically endothelial cells, which have a long history of being utilized to study diabetes and obesity (learn more).

Our new selection offers unique opportunities for disease-specific models, as we've chosen Adipose-Derived Stem Cells (ADSCs), fibroblasts, and hepatic stellate cells isolated from diseased donors. The cells are suited for any researcher studying type 1 diabetes, type 2 diabetes, obesity, or non-alcoholic steatohepatitis (NASH).

Image: Formation of tube networks in Neuromics HRMECs in normal glucose (NG) and high glucose (HG) conditions.

Here are the new cell types:

• ADSCs - Obesity Donor (cat. ADSC001)
• ADSCs - Type 1 Diabetes Donor (cat. ADSC002)
• ADSCs - Type 2 Diabetes Donor (cat. ADSC003)
• Dermal Fibroblasts - Type 1 Diabetes Donor (cat. HDF002)
• Hepatic Stellate Cells - NASH Donor (cat. HHSC001)

If you're using human cell-based assays to research neurodegenerative diseases, your work demands consistent and reliable human neural cells. Neuromics has you covered, with an impressive history of customers using our human cells to study neurodegenerative diseases.

Some examples from the past few years:

• Our primary human neurons (cat. HNC001) linked long COVID to Alzheimer's disease (AD) (check it out).
• The mechanisms connecting periodontitis and AD were explored with our 3D human blood-brain barrier model (cat. 3D45002) (learn more).
• Researchers explored how Semaphorin 4D expression leads to neurodegenerative diseases in our human brain astrocytes (cat. HMP202) (read more).

Image: Neuromics Human Brain Microvascular Endothelial Cells (cat. HEC02) stained with CD146.

Then, just last week, scientists from Imperial College in London used our primary human brain microvascular endothelial cells (HBMECs) (cat. HEC02) in an AD study.

With colorectal cancer (CRC) being one of the most prevalent cancers worldwide, understanding chemotherapy resistance in the CRC tumor microenvironment (TME) is an important goal. As we’ve seen in many other publications using our human cancer-associated fibroblasts (CAFs), CAFs play a huge role in the TME.

Our CAFs have been used in a handful of studies in 2D and 3D TME models, where they demonstrate their ability to complicate treatment objectives. Overall, the mechanisms by which CAFs contribute to chemotherapy resistance in the TME are poorly understood. 

Image: DKK1 expression in Neuromics colorectal CAFs when subjected to chemotherapeutic agents.

Researchers from the University of Kentucky utilized our colorectal CAFs (cat. CAF115) in a new paper examining these mechanisms. In their cell models, they found that CAFs secrete DKK1, a protein associated with tumor growth and metastasis, when subjected to chemotherapy treatments for CRC. Their results identified CAF-secreted DKK1 as a major player in resistance to treatment. Furthermore, they recommend looking into treatments that target DKK1 to counteract chemotherapy resistance.

You can check out the full paper here.

Chronic pain is a condition that affects tens of millions of Americans. Pain management has generally relied on NSAIDS and opioids, both of which have drawbacks. Put simply, novel pain therapeutics are needed.

Collaborating researchers from the University of New Mexico released a study earlier this month about an experimental chronic pain therapeutic. They relied on our Preferred Fetal Bovine Serum (cat. FBS007) for the cell culturing in their study.

Image: Immunostaining of human DRG cultured using Preferred FBS.

The scientists decided to target the P2X4 receptor (P2X4R), known for its role in pain signaling, with a humanized single-chain variable fragment (hscFv) targeting P2X4R. hscFvs are genetically engineered antibody fragments that are starting to become of increased interest in drug discovery.

After culturing human DRG neurons, HEK-293T cells, and HEK-293T cells stably expressing human His-tagged P2X4R with our FBS, the samples were pretreated with the hscFv targeting P2X4R. They found that P2X4R activity and neuronal excitability were both decreased in cells treated with the hscFv compared to the control.

Far and away, the most common research theme with our human cancer associated fibroblasts (CAFs) is 3D. Whether it's 3D co-culture, organoids, or in vivo models, the value of these cells is most apparent when integrated into 3D models that mimic the tumor microenvironment (TME). A new study from scientists at the Federal University of Santa Catarina in Brazil outlines a novel approach for building a 3D platform for co-culturing cells. The investigators utilized our human primary breast CAFs (cat. CAF116) and US origin premium fetal bovine serum (FBS) (cat. FBS001) to make it happen.

Image: 3D confocal microscopy of cells seeded into BNC at different time points: MDA-MB-231 cells (green), Neuromics breast CAF (red), and M2 macrophages (blue). MDA-MB-231 cells and macrophages were grown with Neuromics’ FBS.

The investigators outlined the steps to build a translucent multi-compartmentalized stacked multilayered nanocellulose scaffold. The scaffold consisted of bacterial nanocellulose (BNC) layers separated by interlayers of a lower density of nanocellulose fibers. To validate their scaffold model, they cultured several cell types, including EOMA cells, EA.hy926 cells, MDA-MB-231 cells, monocytes, and macrophages with media supplemented with Neuromics' FBS.

Earlier this year, Cube Biotech GmbH announced its acquisition of Neuromics' longtime partner, IBA Lifesciences. As a result, Neuromics is excited and grateful to introduce Cube Biotech's market-leading membrane protein stabilization and protein purification products to our catalog.

Membrane proteins are key players in drug discovery, with over half of FDA-approved drugs targeting them. However, they are tough to work with and characterize, as they are unstable outside the lipid environment. Detergents have conventionally been the approach to stabilize these proteins, but these approaches are time-consuming and frustrating. 

Cube Biotech takes things to the next level with the NativeMP™ technology. The NativeMP™ technology uses lipids encased by polymers to create a membrane protein's natural lipid environment. With Cube's products, proteins remain active, allowing you to stabilize potential drug targets.

Screening is vital to finding the right copolymer for your proteins of interest. We offer Cube's screening kits, which combine over 30 copolymer belts and are a great starting point.

• NativeMP™ Screening Kit (cat. 18298-CUBE)

Over the years, Neuromics fetal bovine serum (FBS) has been utilized in numerous research papers and projects. One of the main takeaways from the papers is the breadth of cell types and applications that our FBS options enable.

Whether you're working with sensitive primary cells, robust cancer cell lines, stem cells, or anything in between, we undoubtedly have a solution. Furthermore, if your application calls for more than basic FBS, we supply heat-inactivated and specialty options allowing you to satisfy your specific needs.

That trend continues, with a new thesis released this week. In the paper, a student from the University of Arkansas used our heat-inactivated premium imported FBS (cat. FBS002-HI) to culture RTS11 cells, a rainbow trout monocytic cell line, and monocytic cells isolated from rainbow trout kidneys. The research explored how temperature impacts immune function. Learn more here.

Neuroscience, cancer, and pain - these are the three areas where Neuromics products are most prevalent. Last month, researchers from New York University published a study at the intersection of these three fields, using a neural cell type to explore the mechanisms of pain in oral cancer.

Image: TRPV4 is functionally expressed in Neuromics human Schwann cells. Expression is confirmed using TRPV4 agonist GSK1016790A.

Oral cancer is known to often cause a lot of pain when the lesion is touched or pressured, but the cause of this pain is not well understood. When looking at some of the mechanisms of this pain, the scientists employed our primary human Schwann cells (cat. HMP303). The investigation focused on the expression of TRPV4 in Schwann cells, including our Schwann cells. They found that TRPV4 inhibition reduced pain in mouse models, suggesting TRPV4 from activated Schwann cells is a major source of pain in oral cancer. You can read the full study here.

Along with our often-featured human cells, media, and antibodies, Neuromics offers a large selection of recombinant proteins. We'd like to focus on ISOKine recombinant proteins, which use a unique technology for their production. Furthermore, one was used in a newly released study.

Researchers from the Department of Developmental BioEngineering at the University of Twente used our ISOKine Human Fibroblast Growth Factor basic (bFGF) recombinant protein (cat. PR80001) in 3D bioprinting research published earlier this month. The bFGF was used to supplement media for the culture of human mesenchymal stem cells. The scientists introduced a dual cross-linkable hydrogel with the potential to produce engineered tissues, drug discovery models, and lab-grown meat. Read the full study here.

Image: Plant cell system: the barley plant does not contain any pathogens or other components known to be harmful for human or animal stem cells.

ISOKine plant-based proteins are highly purified, endotoxin-free, and produced in an eco-friendly manner. They are all produced in barley grain (Hordeum vulgare), meaning they are free from animal and human components, antibiotics, and contaminants. The proteins are perfect for use in stem cell culture. Read more to explore our options.

As IBA Lifesciences US distributor, Neuromics offers our customers cutting-edge protein purification products. IBA is constantly introducing resins with greater capacity and higher yields. Strep-Tactin® 4Flow® High Capacity is now available as a new and improved version of our top-selling protein purification product.

The new resin consists of a low concentrated (4%) and pressure stable agarose coupled with high Strep-Tactin® density. These specifications lead to:

• High protein binding capacity
• Applicability for FPLC workstations
• High yields for all protein classes, especially large proteins
• Superior stability enabling at least 50 regeneration cycles

As IBA Lifesciences US distributor, Neuromics equips the American market with the very best protein and cell isolation tools, including an assortment of peptides for T-cell stimulation. These peptides are synthesized to activate antigen-specific CD8+ T-cells, enabling infectious diseases, cancer, and autoimmune research, among other areas. They are currently being used by many large pharmas and biotechs in their projects.

Image: Peptide for T-cell stimulation.

The most popular peptides include the NY-ESO-1 peptide SLLMWITQV (cat. 6-7013-901), Ovalbumin peptide SIINFEKL (cat. 6-7015-901), and WT 1 peptide RMFPNAPYL (cat. 6-7019-901). We also have a number of options for SAR-CoV-2 research. You can check them all out here.

While we spend most of our time talking about our human cells, antibodies, media, and fetal bovine serum (FBS), there is a lot more that Neuromics offers to researchers. This includes a variety of transfection kits with applications across a wide variety of focus areas and in experiments both in vitro and in vivo.

Our transfection kits include products specifically designed to be used with certain cell types and cell lines. We encourage you to explore our entire selection of kits here.

Like with our other products, our transfection kits are also research proven. For example, just a couple of months ago, researchers from the University of Georgia College of Pharmacy and Mercer University published new findings using our i-Fect siRNA Delivery Kit (cat. NI35150). i-Fect was used to knockout genes in the spinal cord of rats. The scientists' findings suggest a potential treatment for neuropathic pain.

Read the full publication here. Furthermore, you can find all publications using our transfection kits here. 

At it's heart, Neuromics is a neuroscience company, featuring a variety of reagents perfect for any neuroscientist. However, the applications of our offerings certainly don't stop there - check out the hundreds of publications to see for yourself. Today, we'd like to highlight the products we have available for cancer researchers.

To start, we'd like to point to some research with repurposed neuroscience tools. Glioblastoma research published last month demonstrates our Primary Human Neurons (cat. HNC001) and Human Brain Astrocytes (cat. HMP202) both have applications in cancer research as well. The researchers used our cells to compare the expression of GPC2 in healthy neurons and astrocytes with cancerous tissue when looking at a potential target for therapy. In addition to our cells, the researchers also used media and other culturing products supplied by Neuromics. Check out the full publication here.

Image: GFP Expressing Human Renal Adenocarcinoma Cells (ACHN)

Read more to learn about some of our core cancer related products...

Potent, Proven, and Ready to Use 3-D Models

Neuromics offers Primary Human Cell Based Blood-Brain Barrier (BBB) and Human Umbilical Vein Endothelial Cell (HUVEC) Models.

These models are designed to study specific diseases. There are configured to mimic in-vivo like environments. We provide the cultured cells plates with 3-D inserts. The 3-D environments are optimized for cell growth in 3-D and ready to use for your drug discovery and toxicology assays.

Analytes tested by our customers include small molecules. compounds, proteins, antibodies, viruses, and bacteria.

Custom Models

Customers also use Neuro, Cancer-Associated Fibroblasts (CAFs), Cancer and iPSC-Derived Cells to manufacture organic, and micro-fluidic models.

Neuromics has a wide offering of transfection reagents that are perfect for both in vivo and in vitro applications. We take pride in seeing our product used in research, which is certainly true of our transfection reagents (see here).

Furthermore, we'd like to highlight a recent use of our n-Fect Transfection Kit (cat.# NF30150) in a doctoral thesis recently published. The paper looked into the neuroscience of alcohol addiction, looking towards the purinergic family receptor P2X4, which has been linked to alcohol addiction in mouse models. Using our n-Fect Transfection Kit, the molecular and cellular mechanisms linking P2X4 expression and voluntary alcohol consumption are explored. Our n-Fect reagents were used on brain slices containing the ventral tegmental area (VTA) of mice. They conclude that purinergic control of VTA neurons is a neurotransmitter system that should be further studied as a target for alcohol dependence drugs.

Image: Examples of p-Fect (Cat.# PF3000) transfection in different cell types.

Read more to explore all of our transfection kits...